Tempus AI, Inc. ( TEM ) stock is trading higher on Thursday after the company announced a collaboration with the Institute for Follicular Lymphoma Innovation (IFLI).

What To Know: The collaboration aims to advance targeted therapy development for follicular lymphoma by creating a real-world multimodal data library within Tempus’ data analytics platform. The collaboration will initially focus on generating data for POD24 patients who experience disease progression within 24 months of treatment.

This resource will enable researchers to generate AI-driven insights that could accelerate treatment progress and improve patient outcomes.

What Else: Tempus is expected to report earnings for the 2024 fiscal-year fourth-quarter on February 24 after the market closes. Analysts’ estimate a loss of 20 cents per share and revenue of $203.12 million.

Related Link: CyberArk Q4 Revenue Surges 41%, Subscription And Strong ARR Clock Strong Growth

TEM Price Action: At the time of writing, Tempus shares are trading 14.5% higher at $84.60, according to data from Benzinga Pro.

Image: Courtesy of Tempus AI ( TEM )